Background/Aims: During the occurrence and progression of hepatocellular carcinoma (HCC), phosphotyrosine phosphatases (PTPs) are usually described as tumor suppressors or proto-oncogenes, and to some degree are correlated with the prognosis of HCC. Methods: A total of 321 patients from the Cancer Genome Atlas (TCGA) database and 180 patients from our validated cohort with hepatocellular carcinoma were recruited in this study. Kaplan-Meier, univariate and multivariate Cox proportional hazards model were used to evaluate the risk factors for survival. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) were applied to detect the expression levels of PTP genes. Results: After screening the data of TCGA, we identified five PTPs as HCC overall survival related PTP genes, among which only three (PTPN12, PTPRN, PTPN18) exhibited differential expression levels in our 180 paired HCC and adjacent tissues (P<0.001). Further analysis revealed that expression of PTPN18 was positively, but PTPRN was negatively associated with prognosis of HCC both in TCGA cohort and our own cohort. As to PTPN12, results turned out to be opposite according to HBV status. In detail, higher expression of PTPN12 was associated with better outcome in HBV group but worse prognosis in Non-HBV group. Conclusion: Our results suggested that PTPN12, PTPRN and PTPN18 were independent prognostic factors in HCC.
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Introduction
Hepatocellular carcinoma (HCC), accounting for approximately 80% of all liver cancers [1, 2] , has become the fifth most frequent cancer and ranks third in the commonest causes
Patients and tissues
For the TCGA cohort, gene expression of PTPs and clinical data of TCGA database are available from the website of Cancer Genomics Browser of University of California Santa Cruz (UCSC) (https://genome-cancer. ucsc.edu/). Only primary hepatocellular carcinoma (HCC) patients with complete overall survival data were included in this study. Follow-up was completed on Dec 30, 2016 .
The validated cohort consists of 180 patients with primary HCC, whose fresh HCC tissue samples and paired adjacent non-tumor tissue samples were obtained between 2008 to 2010. They were recruited from the Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University (Nanjing, PR China). There was no recruitment restriction on age, gender, tumor stage and no previous history of other cancers for all patients. All patients underwent hepatic resection within 2 months after diagnosis and no other anticancer treatment before surgery.
Survival Data
The overall survival (OS) was defined as the time from date of diagnosis to death due to any cause. The disease free survival (DFS) was defined as the time from date of diagnosis to date of tumor recurrence, progression or metastasis of HCC. The median follow-up of TCGA cohort and the validated cohort was 561 days (1-3675) and 22 months (1-87) respectively. 
RNA isolation and quantitative real-time PCR (qRT-PCR)
RNAs were extracted from samples by using TRIzol reagent (Invitrogen, Grand Island, NY, USA) as described by the manufacturer, and were reverse transcripted using the PrimeScript RT Master Mix (Takara, Dalian, China). The SYBR Premix Ex Taq (Takara, Dalian, China) was used to perform quantitative real-time PCR on the ABI Prism 7900HT (Applied Biosystems, Foster City, CA, USA). The primer sequences were shown in Table 1 .
Immunohistochemistry (IHC)
The UltraSensitiveTM SP (Mouse/Rabbit) IHC Kit (Maixin Biotech, Fuzhou, China) which uses streptavidin-biotin amplification method was applied to perform immunohistochemical study. After deparaffinizing the 4μm tissue samples, we blocked endogenous peroxidase activity with 0.3% hydrogen and incubated sections with 0.03 mol/l citrate buffer (pH 6.0) in a pressure cooker under 121°C. Nonspecific reaction was blocked by using 10% bovine serum (Biosharp, Hefei, China) for 30 min. Finally, sections were incubated with primary antibody overnight at 4°C and in turn detected with 3.3′-diaminobenzidine (DAB) solution. The primary antibodies we used were listed in Table 1 .
Evaluation of PTPN12, PTPRN, PTPN18 expression in validated cohort
The immunohistochemically stained tissue sections were scored separately by two pathologists blinded to the clinicopathological parameters. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong). Extent of staining was scored as 0 (<5 %), 1(5-25 %), 2 (26-50 %), 3 (51-75 %) and 4 (>75 %) according to the percentages of the positive staining areas in relation to the whole carcinoma area. Scores for staining intensity and percentage positivity of cells were then multiplied to generate the immunoreactivity score (IRS) for each case. Samples having a final staining score of ≤ 4 were considered to be low and those with score of > 4 were considered to be high.
Statistical Analysis
We presented categorical variables as frequency (%), and continuous variables as median (interquartile range). Patients in TCGA cohort were divided into high-expression group and low-expression group according to the median of different PTPs expression at mRNA level. Patients in validated cohort were divided into low (IRS≤ 4) and high (IRS> 4) PTP expression groups according to the immunoreactivity scores of PTPN12, PTPRN and PTPN18 respectively. X-tile 3.6.1 software (Yale University, New Haven, CT, USA) was used to determine the optimal cut-off values for PTPN12 expression in subgroup analysis for TCGA cohort [20] . The relationship between expression of the PTPs and various clinicopathological parameters was analyzed by the χ2 test and Student's t test. The log rank test was employed for the analysis of Kaplan-Meier curves. Clinical characteristics that showed significant association with survival in univariate analysis (P<0.05) were entered into multivariate analysis, which was performed with Cox proportional hazard model. All statistical analyses were conducted with the statistical soſtware package SPSS for Windows, version 17 (SPSS, Inc). P < 0.05 was considered statistically significant.
Results

Clinical factors in TCGA cohorts
A total of 321 hepatocellular carcinoma (HCC) patients were identified from TCGA cohort, among which 214 (66.7%) were male and 107 (33.3%) were female. The median age was 62, ranging from 17 to 90 years old. Patient demographics and pathologic features are summarized in Table 2 . (Table 3 ). The corresponding Kaplan-Meier curves of five PTPs are shown in Fig. 1 .
Expression of PTPN12, PTPRN and PTPN18 exhibited significant difference in HCC and paired adjacent tissues in validated cohort
To verify the reliability of TCGA results, information of 180 in-house eligible patients from the Liver Transplantation Center of the First Affiliated Hospital of Nanjing Medical University were assembled and analyzed as the validated cohort, among which 137 (76.1%) were male patients and 43 (23.9%) were female. Detailed information of age, Hepatitis B surface antigen (HbsAg) status, ALT, AFP, cirrhosis, vascular invasion, tumor size and Edmondson grade are shown in Table  4 .
To further evaluate the clinical value of five candidate PTPs in HCC, quantitative qPCR and immunohistochemistry (IHC) were performed. Compared to adjacent non-tumor tissues, PTPN12 and PTPN18 were significantly downregulated, while PTPRN was upregulated in HCC tissues 3A) . In the validated cohort, PTPN12 expression was associated with HbsAg status, AFP, tumor size and Edmondson grade (P < 0.05), PTPRN expression was associated with vascular invasion, tumor size (P < 0.05), whereas PTPN18 expression was correlated with gender, ALT and Edmondson grade (P < 0.05) ( Table 4) . Univariate Cox proportion hazard ratio analysis indicated that gender, cirrhosis, vascular invasion, tumor size, Edmondson grade were potential prognostic factors in terms of both OS and DFS (Table 5) . Further multivariate analysis after adjustment suggested that expression levels of PTPN12, PTPN18, PTPRN were three independent predictors of both OS (PTPN12 high (Fig. 3B ).
Subgroup analysis of overall survival for PTPN12 according to HBV status in TCGA cohort
As shown in Fig. 1B , 3B, we got diametrically opposed results in term of PTPN12, which has been reported as a HBV associated protein [15, [21] [22] [23] . Moreover, the majority of patients from the TCGA cohort were at the risk of Hepatitis C, Nonalcoholic Fatty Liver Disease (NAFLD) or excessive alcohol consumption, while almost all patients of our validated cohort are Hepatitis B infectors. Therefore, patients from TCGA cohort were redivided into two groups in accordance with HBV status and the optimal cut-off values of PTPN12 expression in each group were determined with X-tile 3. (Table  6 and Table 7 ). Corresponding KaplanMeier analyses were shown in Fig. 4A and 4B.
Discussion
HCC has turned out to be an increasingly serious problem which threatens human health worldwide [1, 24, 25] . In spite of the emerging role of interventional therapy, chemotherapy and immunotherapy, surgical resection remains the cornerstone in the treatment for HCC patients [26] . However, on account of high postoperative recurrence rate, the long-term survival is still unoptimistic, which was reported ranging from 65% to 80% in 5-year after primary surgery [27] . As a result, it increasingly becomes a new focus of research to find the methods for estimating the prognosis of HCC more accurately. Previous study has demonstrated that PTPs functioned as tumor suppressors by removing phosphate moieties on target proteins like RPTPa and PRL family [18] . However, since Zhang SQ characterized SHP2 as the first "oncoPTP" in 2004, more oncogenic PTPs have been described during the last decade. Most of them are regarded as low molecular weight (LMW) PTPs, with a conserved signature motif, CXXXXXRS/T, in their active site, but most other sequences conserved among PTPs lacking [28, 29] . For instance, PTP (CAAX1) and PTP (CAAX2) were upregulated in epithelial cells leading to tumor growth in nude mice and a transformed phenotype in vitro [30] . Interestingly, some of the PTPs like the prototypic PTP1B have been elucidated both their pro-oncogenic and tumor-suppressing characters [18] . However, the mechanism why PTPs function differentially in carcinogenesis haven't yet been completely defined. Furthermore, compared to melanoma and breast cancer, only sporadic researches focused on HCC [31, 32] .
In our study, we investigated the expression levels in HCC and paired adjacent tissues of five PTPs screened from TCGA, and three of them showed significant difference. Further sets. X-tile plots of training sets were shown in the left panels, with plots of matched validation sets shown in the smaller inset. The optimal cut-off values highlighted by the black circles in left panels were also shown in histograms of the entire cohort (middle panels), and Kaplan-Meier plots were displayed in right panels. P values were determined by using the cut-off values defined in training sets and applying them to validation sets. The optimal cut-off values of PTPN12 in two groups for OS were -1.5 and 0.1 respectively. (A) HBV group (n=97) (B) Non-HBV group (n=224). [14, 15, [33] [34] [35] . It is rather remarkable that one of the expression quantitative trait loci (eQTL) for PTPN12 could multiplicatively interact with HBV hotspot mutation, which was suggested to significantly increase the risk of both chronic HBV infection and HBV-related HCC [21] . Moreover, PTPN12 inhibits secondary T-cell responses and is implicated in human autoimmunity, which may be either beneficial or detrimental to those infected with HBV [22, 23] . All these findings highlight the importance of PTPN12 in the development of HBV-related HCC. In our study, we came to completely opposite conclusions on the relationship between PTPN12 and prognosis in two different cohorts, subgroup analysis of TCGA cohort according to HBV status indicated that differentiation of risk factors in this two cohort might partly contribute to this discrepancy. Considering that HBV infection is still the main risk factor of HCC in China [24] , it will be of dramatic significance to explore the association between the interaction of PTPN12 with HBV mutation and the repressive function of PTPN12 in HCC. Furthermore, whether PTPN12 can be targeted for clinical treatment to chronic HBV infection and be applied to terminate the inflammation-carcinoma transformation in HCC deserves extended studies.
PTPRN is a transmembrane PTP, which locates on the long arm of human chromosome 2 (2q35) [36] . Previous researches demonstrated that PTPRN was processed in secretory granule of pancreatic islets and other neuroendocrine cells, which quite possibly accounted for its significant correlation with diabetes [37] . However, the relationship between PTPRN and cancers remains illy defined. On contrary to other two PTPs in our study, PTPRN was negatively related to the survival of HCC patients, which corresponded to the data from TCGA. Therefore, all these results indicated the role of PTPRN in liver tumorigenesis, while the precise mechanism is yet to be illuminated.
PTPN18, also named BDP1, belongs to the small sub-family of PEST domain-containing PTPs. It was primarily identified as a negative regulator in tyrosine-specific phosphorylation of HER2, which was implicated in the mediation of important cellular functions like cell survival, proliferation, polarity and migration [38] [39] [40] . Recently, much attention was paid to its role in different cancers [41] [42] [43] . For instance, it was reported to suppress the invasive and metastatic ability of HER2 overexpression breast cancer, and lead to the cancer specific splice variations in thyroid cancers like FTA, FTC, and FVPTC [41, 43] . More interestingly, Meir et al. found that compared to the primary tumor, the expressions of PTPN18 as well as other six genes were up-regulated in liver metastases of uveal melanoma according to the microarray results, which indicated its involvement in distant colonization of cancer cell [44] . Though our study suggested its potential to be a tumor suppressor and prognosis indicator in HCC, more studies are required to uncover the accurate mechanism.
In spite that conclusions made from two independent cohorts were convincing owing to large sample capacity and relative long-term follow-up, certain limitations still should be considered that several prognosis-related risk factors were not included in the TCGA cohort like tumor size, chemotherapy and cirrhosis status, which might also partly contribute to the contrary results of PTPN12 in two different cohorts. Second, considering the complex network of different signal pathways in vivo, critical roles of other PTPs excluded in this study could not be denied.
Taken together, of the five genes we screened from TCGA, three showed significant difference in the expression levels between HCC and paired adjacent tissues. Expression of PTPN18 was positively, while PTPRN was negatively related to prognosis of HCC. As to PTPN12, results turned out to be opposite according to HBV status. In detail, higher expression of PTPN12 was associated with better outcome in HBV group but worse prognosis in Non-HBV group. Combined with the previous studies, these findings highlight the importance of
